-
2023-504176-25-00
9
2024-08-08
Acute Myeloid Leukemia
-
2024-513718-37-00
4
2024-08-01
IGHV unmutated patients with high-risk stage A CLL features.
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2023-505655-43-00
7
2024-07-29
Metastatic neuroendocrine prostate cancer
-
2023-507204-31-00
5
2024-07-26
Hidradenitis Suppurativa
-
2023-503594-38-00
1
2024-07-15
Select B-Cell malignancies.
-
2023-505061-82-01
5
2024-06-17
Alopecia Areata
-
2023-508235-31-00
5
2024-06-17
Atopic Dermatitis
-
2023-503666-23-00
5
2024-06-07
Neovascular age-related macular degeneration
-
2023-508426-10-00
3
2024-06-03
Relapsed/Refractory Multiple Myeloma
-
2022-501234-37-00
7
2024-05-07
Solid Tumours
-
2023-506735-15-00
5
2024-04-05
Erythropoietic Protoporphyria or X-Linked Protoporphyria
-
2023-506948-17-00
5
2024-04-05
Previously Untreated Chronic Lymphocytic Leukemia
-
2023-505515-21-00
5
2024-04-02
Giant Cell Arteritis
-
2022-502161-19-00
5
2024-03-12
Chronic Spontaneous Urticaria
-
2022-502446-27-00
5
2024-02-26
Relapsed or Refractory Myeloma
-
2022-501372-25-00
4
2024-01-10
Patients aged 18 years and older with relapsed or refractory FLT3 muta
-
2023-503669-50-00
5
2023-12-27
Moderate-to-Severe Thyroid Eye Disease
-
2022-501406-36-00
3
2023-12-14
Myeloid disease
-
2024-514876-41-00
9
2023-12-06
Higher-risk myelodysplastic syndromes untreated and ineligible for all
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2023-503952-28-00
4
2023-11-13
Steroid refractory Acute Graft versus host Disease
-
2023-507672-52-00
7
2023-11-07
PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and
-
2023-503422-39-00
5
2023-10-20
Hepatocellular Carcinoma (HCC)